Advertisement
Australia markets close in 6 hours 6 minutes
  • ALL ORDS

    7,898.90
    +37.90 (+0.48%)
     
  • ASX 200

    7,642.10
    +36.50 (+0.48%)
     
  • AUD/USD

    0.6423
    -0.0003 (-0.04%)
     
  • OIL

    82.60
    -0.13 (-0.16%)
     
  • GOLD

    2,395.00
    -3.00 (-0.13%)
     
  • Bitcoin AUD

    98,601.92
    +3,058.91 (+3.20%)
     
  • CMC Crypto 200

    1,311.14
    +425.60 (+48.06%)
     
  • AUD/EUR

    0.6034
    +0.0003 (+0.05%)
     
  • AUD/NZD

    1.0879
    +0.0004 (+0.04%)
     
  • NZX 50

    11,807.92
    -28.12 (-0.24%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,837.40
    +67.38 (+0.38%)
     
  • Hang Seng

    16,385.87
    +134.03 (+0.82%)
     
  • NIKKEI 225

    38,079.70
    0.00 (0.00%)
     

Monster Beverage Keeps Us Going at Home, Driving Sales Higher

By Christiana Sciaudone

Investing.com -- Looks like we know what's fueling those people working extra hours during lockdowns.

Monster Beverage (NASDAQ:MNST) rose more than 5% after beating estimates and reporting an improvement in sales in the latter half of the second quarter with cities reopening and consumers buying more energy drinks to consume at home.

The company’s e-commerce, club store, mass merchandiser and grocery and related business continued to increase in the quarter while its food service on-premise business, which is a small channel for the company, remained challenged, Monster said in a statement.

ADVERTISEMENT

Bank of America (NYSE:BAC) also lifted its estimates for Monster, which it rates a buy, according to Seeking Alpha. Analyst Peter Galbo cited the company's "reaccelerating growth" as warranting a higher valuation multiple. He raised the multiple to 37 times 2021 estimated earnings per share from 34 times, and bumped the price target to $95 from $80.

Net sales for the quarter were $1.09 billion compared with $1.10 billion in the same period last year, and versus the $1 billion average analyst estimate. Earnings per share of 59 cents beat the 48-cent forecast.

Related Articles

U.S. to pay $1 billion for 100 million doses of Johnson & Johnson's COVID-19 vaccine candidate

Wall St. rises on Disney's surprise profit, services sector data

U.S. Treasury to sell $112 billion next week, continue shift to longer-dated debt